Moossa AR - Search Results

1

Ampullary pancreatoblastoma in an elderly patient: a case report and review of the literature.

Du E, Katz M, Weidner N, Yoder S, Moossa AR, Shabaik A. Du E, et al. Among authors: moossa ar. Arch Pathol Lab Med. 2003 Nov;127(11):1501-5. doi: 10.5858/2003-127-1501-APIAEP. Arch Pathol Lab Med. 2003. PMID: 14567752 Free article. Review.

2

Simultaneous serous cystadenoma of the pancreas and mucinous cystadenoma of the appendix.

Alrefaie W, Katz MH, Easter DW, Yi ES, Weidner N, Savides TJ, Moossa AR, Bouvet M. Alrefaie W, et al. Among authors: moossa ar. JOP. 2004 Mar;5(2):97-100. JOP. 2004. PMID: 15007191

3

Non-pancreatic periampullary adenocarcinomas: an explanation for favorable prognosis.

Katz MH, Bouvet M, Al-Refaie W, Gilpin EA, Moossa AR. Katz MH, et al. Among authors: moossa ar. Hepatogastroenterology. 2004 May-Jun;51(57):842-6. Hepatogastroenterology. 2004. PMID: 15143931

4

An evidence-based approach to the diagnosis and staging of pancreatic cancer.

Katz MH, Savides TJ, Moossa AR, Bouvet M. Katz MH, et al. Among authors: moossa ar. Pancreatology. 2005;5(6):576-90. doi: 10.1159/000087500. Epub 2005 Aug 16. Pancreatology. 2005. PMID: 16110256

5

An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer.

Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. Katz MH, et al. Among authors: moossa ar. Clin Exp Metastasis. 2004;21(1):7-12. doi: 10.1023/b:clin.0000017160.93812.3b. Clin Exp Metastasis. 2004. PMID: 15065597

6

Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer.

Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. Katz MH, et al. Among authors: moossa ar. Cancer Res. 2003 Sep 1;63(17):5521-5. Cancer Res. 2003. PMID: 14500389

7

Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer.

Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. Katz MH, et al. Among authors: moossa ar. Cancer Res. 2004 Mar 1;64(5):1828-33. doi: 10.1158/0008-5472.can-03-3350. Cancer Res. 2004. PMID: 14996746

8

A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.

Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. Katz MH, et al. Among authors: moossa ar. J Surg Res. 2003 Jul;113(1):151-60. doi: 10.1016/s0022-4804(03)00234-8. J Surg Res. 2003. PMID: 12943825

9

High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer.

Bouvet M, Spernyak J, Katz MH, Mazurchuk RV, Takimoto S, Bernacki R, Rustum YM, Moossa AR, Hoffman RM. Bouvet M, et al. Among authors: moossa ar. Cancer Res. 2005 Nov 1;65(21):9829-33. doi: 10.1158/0008-5472.CAN-05-1548. Cancer Res. 2005. PMID: 16267005 Free article.

10

Common bile duct injection as a novel method for establishing red fluorescent protein (RFP)-expressing human pancreatic cancer in nude mice.

Tsuji K, Yang M, Jiang P, Maitra A, Kaushal S, Yamauchi K, Katz MH, Moossa AR, Hoffman RM, Bouvet M. Tsuji K, et al. Among authors: moossa ar. JOP. 2006 Mar 9;7(2):193-9. JOP. 2006. PMID: 16525203

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

232 results

Search Page

Filters